Kindstar Globalgene Announces FY2021 Annual Results, Revenue Increases to RMB930.67 Million
During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%.
- During the period under review, the Group recorded total revenue of RMB930.67 million, representing a year-on-year increase of 4.4%.
- During the period, the Group achieved revenue of RMB535.27 million and segment results of RMB152.57 million, representing a year-on-year increase of 14% and 15.7%, respectively.
- The Group recorded revenue of RMB89.85 million and segment results of RMB14.06 million during the period, a year-on-year increase of 18.2 and 11.6%, respectively.
- Kindstar Globalgene 2021 Annual Results Announcement:
Infographics for Kindstar Globalgene 2021 Annual Results Announcement:
Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Group"; stock code: 9960.HK) is a leading independent esoteric clinical testing service provider and a major provider of hematology esoteric testing services in China.